Total Payments
$132.70
2022 Payments
$25.97
Companies
5
Transactions
7
Medicare Patients
7,913
Medicare Billing
$635,437
Payment Breakdown by Category
Food & Beverage$132.70 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $132.70 | 7 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $46.85 | 3 | $0 (2020) |
| Boston Scientific Corporation | $25.97 | 1 | $0 (2022) |
| Amgen Inc. | $23.01 | 1 | $0 (2018) |
| Neos Therapeutics, LP | $19.80 | 1 | $0 (2017) |
| Genentech USA, Inc. | $17.07 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $25.97 | 1 | Boston Scientific Corporation ($25.97) |
| 2020 | $16.15 | 1 | Merck Sharp & Dohme Corporation ($16.15) |
| 2018 | $70.78 | 4 | Merck Sharp & Dohme Corporation ($30.70) |
| 2017 | $19.80 | 1 | Neos Therapeutics, LP ($19.80) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/10/2022 | Boston Scientific Corporation | General - Pain Management (Device) | Food and Beverage | In-kind items and services | $25.97 | General |
| Category: General - Pain Management_NMD | ||||||
| 01/23/2020 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), STEGLATRO, STEGLUJAN | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/21/2018 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Virology & Specialty Care | ||||||
| 07/31/2018 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), STEGLATRO, DULERA | Food and Beverage | In-kind items and services | $12.57 | General |
| Category: ENDOCRINOLOGY | ||||||
| 07/17/2018 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: Cardiology | ||||||
| 02/13/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: ONCOLOGY | ||||||
| 06/15/2017 | Neos Therapeutics, LP | Adzenys XR-ODT (Drug) | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: ADHD | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 556 | 815 | $105,932 | $36,038 |
| 2022 | 12 | 2,734 | 4,832 | $659,688 | $227,688 |
| 2021 | 20 | 3,017 | 5,313 | $591,262 | $231,345 |
| 2020 | 20 | 1,606 | 3,068 | $366,904 | $140,367 |
Total Patients
7,913
Total Services
14,028
Medicare Billing
$635,437
Procedure Codes
66
All Medicare Procedures & Services
66 procedure records from CMS Medicare Utilization — Page 2 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 87651 | Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | Office | 2022 | 13 | 14 | $1,198 | $486.01 | 40.6% |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | Office | 2021 | 849 | 1,032 | $210,425 | $77,325 | 36.7% |
| 87798 | Detection test by nucleic acid for organism, amplified probe technique | Office | 2021 | 256 | 1,856 | $152,939 | $64,408 | 42.1% |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | Office | 2021 | 779 | 947 | $87,004 | $23,675 | 27.2% |
| 87631 | Detection test by nucleic acid for multiple types of respiratory virus, multiple types or subtypes, 3-5 targets | Office | 2021 | 163 | 166 | $51,852 | $23,517 | 45.4% |
| 87486 | Detection test by nucleic acid for chlamydia pneumoniae, amplified probe technique | Office | 2021 | 202 | 213 | $17,711 | $7,404 | 41.8% |
| 87581 | Detection test by nucleic acid for mycoplasma pneumoniae (bacteria), amplified probe technique | Office | 2021 | 200 | 211 | $17,535 | $7,334 | 41.8% |
| 87640 | Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | Office | 2021 | 162 | 178 | $14,005 | $6,211 | 44.3% |
| 87801 | Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | Office | 2021 | 64 | 79 | $8,507 | $4,949 | 58.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 30 | 33 | $6,219 | $3,331 | 53.6% |
| 87481 | Detection test for candida species (yeast), amplified probe technique | Office | 2021 | 57 | 70 | $4,556 | $2,456 | 53.9% |
| 87653 | Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | Office | 2021 | 58 | 66 | $4,473 | $2,316 | 51.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 15 | 15 | $3,585 | $2,126 | 59.3% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 17 | 17 | $2,809 | $1,743 | 62.0% |
| 87500 | Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | Office | 2021 | 46 | 49 | $3,903 | $1,719 | 44.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 17 | 17 | $2,308 | $1,359 | 58.9% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 33 | 56 | $1,178 | $564.20 | 47.9% |
| 71046 | X-ray of chest, 2 views | Office | 2021 | 19 | 24 | $1,197 | $430.78 | 36.0% |
| 87804 | Detection test by immunoassay for influenza virus | Office | 2021 | 13 | 26 | $702.00 | $430.30 | 61.3% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2021 | 19 | 78 | $174.00 | $28.36 | 16.3% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2021 | 18 | 180 | $180.00 | $18.23 | 10.1% |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | Office | 2020 | 629 | 803 | $201,950 | $80,200 | 39.7% |
| 87798 | Detection test for organism | Office | 2020 | 79 | 567 | $49,826 | $19,896 | 39.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 113 | 122 | $23,533 | $9,208 | 39.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 62 | 62 | $18,828 | $7,419 | 39.4% |
About Dr. Jason Junkins, M.D
Dr. Jason Junkins, M.D is a Internal Medicine healthcare provider based in Rainbow City, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1114928512.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jason Junkins, M.D has received a total of $132.70 in payments from pharmaceutical and medical device companies, with $25.97 received in 2022. These payments were reported across 7 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($132.70).
As a Medicare-enrolled provider, Junkins has provided services to 7,913 Medicare beneficiaries, totaling 14,028 services with total Medicare billing of $635,437. Data is available for 4 years (2020–2023), covering 66 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Rainbow City, AL
- Active Since 08/09/2005
- Last Updated 03/12/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1114928512
Products in Payments
- JANUVIA (Drug) $28.72
- General - Pain Management (Device) $25.97
- Repatha (Biological) $23.01
- Adzenys XR-ODT (Drug) $19.80
- KEYTRUDA (Biological) $18.13
- Xofluza (Drug) $17.07
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.